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human endocytic receptor DEC-205 stimulates protective T-cell
responses
Abstract
Dendritic cells (DCs) express many endocytic receptors that deliver antigens for major
histocompatibility class (MHC) I and II presentation to CD8(+) and CD4(+) T cells, respectively. Here,
we show that targeting Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) to one of them, the human
multilectin DEC-205 receptor, in the presence of the DC maturation stimulus poly(I:C), expanded
EBNA1-specific CD4(+) and CD8(+) memory T cells, and these lymphocytes could control the
outgrowth of autologous EBV-infected B cells in vitro. In addition, using a novel mouse model with
reconstituted human immune system components, we demonstrated that vaccination with
alphaDEC-205-EBNA1 antibodies primed EBNA1-specific IFN-gamma-secreting T cells and also
induced anti-EBNA1 antibodies in a subset of immunized mice. Because EBNA1 is the one EBV
antigen that is expressed in all proliferating cells infected with this virus, our data suggest that DEC-205
targeting should be explored as a vaccination approach against symptomatic primary EBV infection and
against EBV-associated malignancies.
IMMUNOBIOLOGY
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Dendritic cells (DCs) express many endo-
cytic receptors that deliver antigens for
major histocompatibility class (MHC) I
and II presentation to CD8 and CD4
T cells, respectively. Here, we show that
targeting Epstein-Barr virus (EBV) nuclear
antigen 1 (EBNA1) to one of them, the
human multilectin DEC-205 receptor, in
the presence of the DC maturation stimu-
lus poly(I:C), expanded EBNA1-specific
CD4 and CD8memory T cells, and these
lymphocytes could control the outgrowth
of autologous EBV-infected B cells in
vitro. In addition, using a novel mouse
model with reconstituted human immune
system components, we demonstrated
that vaccination with DEC-205-EBNA1
antibodies primed EBNA1-specific IFN-–
secreting T cells and also induced anti-
EBNA1 antibodies in a subset of immu-
nized mice. Because EBNA1 is the one
EBV antigen that is expressed in all prolif-
erating cells infected with this virus, our
data suggest that DEC-205 targeting
should be explored as a vaccination ap-
proach against symptomatic primary EBV
infection and against EBV-associated ma-
lignancies. (Blood. 2008;112:1231-1239)
Introduction
Epstein-Barr virus (EBV) is a ubiquitous human -herpesvirus that
latently infects B cells and establishes chronic infection in more
than 90% of the adult population. Although infection with EBV
during adolescence can lead to infectious mononucleosis (IM), the
vast majority of infected people acquires and harbors EBV as a
benign lifelong infection, which is controlled by strong T-cell
immunity. However, in a small subset of infected individuals, EBV
latency programs with different viral antigen expression patterns
are associated with malignancies such as Hodgkin and Burkitt
lymphomas as well as nasopharyngeal carcinoma (NPC).1 The
nuclear antigen 1 (EBNA1) is the one EBV antigen that is
expressed in all of these EBV-associated tumors as well as in
EBV-positive proliferating cells in healthy carriers.2 EBNA1 is
crucial for viral persistence, because it initiates viral DNA replica-
tion and anchors the circular viral episome to the mitotic chromo-
somes during cell division, thereby ensuring the survival of the
viral genome in proliferating cells. Thus, even in the absence of all
other EBV proteins, such as in Burkitt lymphoma, EBNA1
expression must be maintained, and from an immune surveillance
point of view, EBNA1 should be a critical target of protective
immunity. Indeed, EBNA1 is consistently recognized by Th1-type
CD4 T cells,3-6 and can elicit CD8 T-cell responses7-9 in healthy
EBV carriers. These T cells that recognize mostly epitopes in the
C-terminal domain of EBNA1 can target EBV-transformed B cells
and prevent their outgrowth in vitro.10 While EBNA1-specific
T-cell responses can also be detected in peripheral blood of NPC
patients,11 they are greatly diminished in patients with EBV-
associated non-Hodgkin lymphoma in the context of HIV infec-
tion,12 EBV-associated Hodgkin disease (K. N. Heller, F.A.,
P. Steinherz, C. Postlook, A. Chadburn, K. Kelly, C.M., manuscript
submitted) and endemic Burkitt lymphomas (Ann Moormann,
Case Western Reserve University, Cleveland, OH, personal commu-
nication April 2008), thus making EBNA1, and specifically its
C-terminal domain, a logical target for vaccine development
against all EBV-associated malignancies.
A promising cell type, to which EBNA1 could be targeted for
vaccine design, is dendritic cells (DCs). These sentinels of the
immune system have an exceptional T-cell stimulatory capacity,
which includes their ability to efficiently process antigens, and
present them on both major histocompatibility class (MHC) I and
class II molecules in combination with T-cell costimulatory mol-
ecules.13 DCs are also crucial for initiating protective innate and
adaptive immune responses against bacterial and viral pathogens in
vivo,14,15 which further supports targeting DCs for therapeutic
vaccination. However, many current DC-targeted immunization
approaches use individualized culture, antigen loading, and activa-
tion of DCs in vitro for adoptive transfer.16 A more recent strategy
that circumvents the analysis of ex vivo DCs is to target antigens to
DCs in vivo by incorporating specific microbial or tumor antigens
into antibodies against DC endocytic receptors, and inject them
with suitable adjuvant formulations.13
One such receptor, DEC-205, is an endocytic type I transmem-
brane multilectin protein that delivers antigens to late endosomes
or lysosomes, which leads to degradation and presentation of
antigens on MHC class II molecules.17,18 DEC-205 can mediate
antigen cross-presentation on MHC class I molecules, which
results in CD8 T-cell stimulation.19,20 In mice, in vivo targeting of
antigens to DEC-205 enhances the efficiency of antigen presenta-
tion to both CD4 and CD8 T cells by approximately 100-
fold.18,19 DEC-205 is also expressed on human monocyte-derived
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DCs as well as on DCs in the T-cell areas of human lymph nodes
and spleen, where they are ideally positioned to stimulate T cells.21
In addition, coupling of the vaccine antigen HIV gag to an
antihuman DEC-205 antibody led to efficient cross-presentation on
MHC class I molecules to cultured CD8 T cells.22 To test the
hypothesis that antigen targeting to DEC-205 would also elicit protec-
tive T-cell responses in humans, we decided to target a dominant CD4
T-cell antigen—in our case the immunogenic C-terminal domain of
EBNA1 (amino acids [aas] 400-641)—to the DEC-205 endocytic
receptor as a first step to develop this strategy for vaccine
development against EBV-associated malignancies.
We will show that the targeting of EBNA1 to DEC-205 expands
protective EBNA1-specific T cells in vitro and primes EBNA1-
specific T cells and antibody responses in vivo.DEC-205-EBNA1–
loaded DCs are consistently more efficient in expanding IFN-–
secreting EBNA1-specific CD4 as well as CD8T cells compared
with isotype control-EBNA1–loaded DCs. In addition, the DEC-
205–targeted fusion antibody stimulates EBNA1-specific T cells
more efficiently from bulk peripheral blood mononuclear cell
(PBMC) cultures, and these expanded T cells are able to control
outgrowth of autologous EBV-transformed B cells. Furthermore,
we can detect EBNA1-specific IFN-–secreting T cells as well as
anti-EBNA1 antibodies after intraperitoneal DEC-205-EBNA1
vaccination of mice with reconstituted human immune system
components, whereas the isotype antibody coupled to EBNA1 does
not elicit any responses in vivo. Collectively, these data suggest
that targeting EBNA1 to the DEC-205 endocytic receptor expands
protective T-cell responses against this crucial viral antigen, and




The research study was approved under IRB protocol number CMU-0478.
293T cells were cultured in Dulbecco modified Eagle medium (DMEM)
plus 10% fetal calf serum (FCS) 2 mg/mL gentamycin. The generation of
CHO-NEO cells was described previously,23,24 and CHO-huDEC205 cells
were generated similarly. In brief, a cDNA fragment encoding mature
human DEC-205 (huDEC-205) was cloned from the human thymic cDNA
library purchased from Clontech (Mountain View, CA) by polymerase
chain reaction (PCR) and sequenced. Sequences of a signal peptide and a
V5 epitope tag were inserted into the N-terminal side of mature huDEC-205
cDNA (GenBank accession no. AY68209125) and subsequently into the
pCMV mammalian expression vector (Clontech). Then, CHO-huDEC-205
cells were generated by transfection with pCMV-huDEC-205 with Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) followed by selection of G418
(1.5 mg/mL) in culture with DMEM medium supplemented with 10% FCS
and 1 GIBCO antibiotic-antimycotic solution (Invitrogen).
Cloning and production of fusion EBNA1 mAbs
Antihuman DEC-205 and the IgG2b isotype control antibody to mouse I-Ak
were cloned from total RNA from the MG38.226 and 10-2.16 (TIB93;
ATCC, Manassas, VA) hybridomas, respectively, as described earlier.22
cDNA coding for EBNA1 amino acids 400 to 641 followed by a 6His tag
was cloned in frame into the COOH terminus of the anti–DEC-205 and the
control mAb heavy chains. Unconjugated anti–DEC-205 mAb produced by
stably transfected 293T cells was purified on Protein G columns (GE
Healthcare, Little Chalfont, United Kingdom). Fusion mAbs were produced
by transient transfection (calcium phosphate) in 293T cells, purified on
high-performance nickel sepharose columns (GE Healthcare), and charac-
terized by SDS–polyacrylamide gel electrophoresis (PAGE) and Western
blotting using anti-EBNA1 (1H4; a gift from Dr Friedrich Gra¨sser, University of
Saarland, Homburg, Germany). The fusion antibodies were tested for binding to
CHO cells transfected to express the human DEC-205 receptor, and to human
monocyte-derived immature DCs by flow cytometry using a phycoerythrin-
conjugated goat-mouse IgG secondary antibody (Biosource, Camarillo, CA).
Peptide libraries
Overlapping peptides of 12- to 22-aa length (average of 15-aa length) with
11-aa overlap were designed for the EBNA1400-641 sequence of the B95.8
EBV strain27 and the MP1 sequence of the influenza A/PR8/34 strain28
using the peptide generator tool of the HIV Sequence Database at the Los
Alamos National Laboratory (http://www.hiv.lanl.gov/content/sequence/
PEPTGEN/peptgen.html29), and synthesized as previously described.27
Preparation of human monocyte-derived dendritic cells and
T cells
PBMCs were isolated from leukocyte concentrates (New York Blood
Center, New York, NY) by density-gradient centrifugation on Ficoll/
Hypaque. CD14 cells were isolated from PBMCs by positive magnetic
cell separation (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany)
and cultured for 5 days in RPMI1640, 2% plasma from healthy laboratory
donors, gentamicin, IL-4, and granulocyte-macrophage colony-stimulating
factor (GM-CSF) to generate immature DCs according to standard proto-
cols.30 The CD14 cells were frozen for later use as a source of bulk T cells.
Immunofluorescence
Human spleen sections were prepared for immunofluorescence as described
previously.21 The sections were stained with unconjugated antihuman
DEC-205 as a positive control and with the indicated fusion antibodies.
T-cell areas were identified using an antibody against CD3 (clone SK7,
IgG1; BD Biosciences, San Jose, CA). After staining with the primary
antibodies, sections were stained with Alexa Fluor 488 or Alexa Fluor 568
conjugated antimouse subclass-specific secondary antibodies (Molecular
Probes, Eugene, OR). Slides were analyzed on an inverted Olympus AX70
microscope (Melville, NY) running MetaMorph software version 6.3r6
(Universal Imaging Corporation, West Chester, PA).
Murine splenic tissue was frozen in OCT compound (Sakura
Finetechnical, Tokyo, Japan); 5-m sections were prepared using a
Microm cryostat (Microm Laborgerate, Walldorf, Germany) and fixed in
acetone. After rehydration in phosphate-buffered saline (PBS), the
sections were blocked with the Zymed endogenous avidin/biotin
blocking kit (Invitrogen) and stained with the primary antibodies:
DEC-205 (clone MG38; Biolegend, San Diego, CA), CD11c (3.9;
Biolegend), and HLA class II (hybridoma IVA12; ATCC). After
washing with PBS, the sections were stained with Alexa Fluor 555–
conjugated streptavidin (Invitrogen) and fluorescein-conjugated strepta-
vidin using the Vector MOM Fluorescein Kit (Vector Labs, Burlingame,
CA). Slides were analyzed as described in the previous paragraph.
Expansion of EBNA1-specific T cells in DC/T-cell cocultures
and PBMCs
Immature monocyte-derived DCs at day 5 of culture in GM-CSF and IL-4
were pulsed with medium, EBNA1 peptides (1 g/mL), DEC-205-
EBNA1, or control Ig-EBNA1 at 1 g/mL with 25 g/mL polyinosinic-
polycytidylic acid (poly(I:C); Invivogen, San Diego, CA) as a DC
maturation stimulus. Forty-eight hours later, autologous CD14 cells were
thawed and cultured with the matured DCs at a DC/T ratio of 1:100 in
RPMI1640 with 5% pooled human serum (PHS) and gentamicin. The
cocultures were incubated for 9 days and then an aliquot of each sample
was restimulated with EBNA1 peptides (1 g/mL per peptide) in the
presence of brefeldin A for 6 hours to block cytokine secretion. The cells
were fixed, permeabilized with 0.1% saponin, and stained with the
fluorochrome-conjugated antibodies: CD8-fluorescein isothiocyanate
(FITC; clone SK1; BD Biosciences), IFN--phycoerythrin (PE; 4S.B3;
eBioscience, San Diego, CA), CD3-PE-Cy5.5 (S4.1; Invitrogen), and
CD4-allophycocyanin (APC; RPA-T4; BD Biosciences). Fluorescence-
activated cell sorting (FACS) analysis was done using a BD Biosciences
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LSR II with Diva software. The remainder of the cells that were not used
for intracellular cytokine staining were labeled with carboxyfluorescein
diacetate succinimidyl ester (CFSE) and restimulated with EBNA1
peptides (1 g/mL per peptide) for an additional 6 days. Proliferation of
T cells was evaluated by CFSE dilution and staining with the fluoro-
chrome-conjugated antibodies: CD8-PE (SK1; BD Biosciences), CD3-
PECy5.5, and CD4-APC. Cells were then analyzed on a BD Bio-
sciences LSR II using Diva software.
To check for the expansion of EBNA1-specific T cells from PBMCs,
freshly prepared PBMCs were plated at a density of 2 106 cells/well in
48-well plates in RPMI1640 with 5% PHS, gentamicin, and 10 U/mL IL-2,
and stimulated with medium, DEC-205-EBNA1, or control Ig-EBNA1 at
5 g/mL with 25 g/mL poly(I:C) as a maturation stimulus for the blood
DCs. IFN- secretion on day 9 and CFSE dilution on day 15 were evaluated
as described in the previous paragraph.
EBV infection of B cells in the presence of expanded
EBNA1-specific T cells
Freshly isolated bulk PBMCs were stimulated with medium, 5 g/mL
DEC-205-EBNA1, or isotype-EBNA1 in combination with 25 g/mL
poly(I:C) and 10 U/mL IL-2. After 9 days, the cells were restimulated and
expanded with EBNA1 peptides and 10 U/mL IL-2 for an additional 6 days.
Autologous CD19 B cells were purified from PBMCs by positive
magnetic cell separation (Miltenyi Biotech, Bergisch-Gladbach, Germany),
infected with EBV overnight using filtered supernatants of the EBV B95-8
marmoset cell line, washed, and added into the expanded T-cell cultures at a
B/T-cell ratio of 2:1; supplemented with 10 U IL-2, 10 ng/mL IL-7, and
10 ng/mL IL-15. After 16 days of coculture, the cells were fixed and stained
with CD19-APC (HIB19; BD Biosciences), CD23-PE (M-L233; BD
Biosciences) and analyzed by FACS to determine the percentage of
EBV-infected B cells.
Preparation of humanized mice and DEC-205-EBNA1
vaccination
NOD/LtSz-scid IL2Rnull (NOG) mice were obtained from The Jackson
Laboratory (Bar Harbor, ME) and raised under pathogen-free conditions.
Human fetal liver was obtained from Advanced Bioscience Resources
(Alameda, CA). The tissue was minced and treated with 2 mg/mL
collagenase D (Roche Diagnostics, Indianapolis, IN) in Hanks balanced salt
solution with CaCl2/MgCl2 for 30 minutes at room temperature followed by
filtering through 70-m nylon cell strainers (BD Biosciences). CD34
human hematopoietic stem cells (HSCs) were isolated using the Direct
CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec). NOG mice (2 to
5 days old) were irradiated with 100 cGy and injected intrahepatically with
1 to 3 105 CD34 HSCs 6 hours after irradiation. The mice were bled 10
to 12 weeks after engraftment and peripheral lymphocytes were analyzed
by FACS as described previously to check for the reconstitution of the
human immune system.31,32 To test the in vivo efficacy of DEC-205
targeting, humanized NOG mice were injected intraperitoneally with PBS
control, 5 g DEC-205-EBNA1, or isotype-EBNA1 with 50 g poly(I:C)
as an adjuvant; the animals were boosted with the same dose of antibodies
and adjuvant a month later. One to 3 months after boost, the mice were
killed, and EBNA1-specific T- and B-cell responses were analyzed in
splenocytes and plasma using an IFN- enzyme-linked immunosorbent
spot (ELISPOT) and EBNA1-specific enzyme-linked immunosorbent assay
(ELISA) assays, respectively.
IFN- ELISPOT and EBNA1 Ig ELISA
ELISPOT assays for IFN- were performed as described previously.4 Bulk
splenocytes from vaccinated mice were seeded at 2 105/well and
stimulated in triplicate with either EBNA1 peptides or an influenza matrix
protein 1 (MP1) peptide library for 18 hours. Spots were counted with an
ELISPOT reader (Autoimmun Diagnostika, Strassberg, Germany). For the
detection of EBNA1-specific IgM and IgG antibodies, sera from vaccinated
mice were tested using a commercially available EBNA1 Ig ELISA kit
(Diamedix, Miami, FL). As suggested in the manufacturer’s instructions, an
index value of 1.10 or higher was used as proof of human EBNA1-specific Ig.
Statistical analysis
Statistical analyses were performed with the paired 2-tailed Student t test.
The P value of significant differences is reported. Plotted data represent
mean plus standard deviation (SD), unless otherwise stated.
Results
Production of the DEC-205-EBNA1 fusion antibody
To target the immunogenic C-terminal domain of EBNA1 (aas 400-641)
to the DEC-205 endocytic receptor, we cloned a cDNAencoding for this
domain with a C-terminal 6His tag to the carboxyl terminus of the heavy
chain of the antihuman DEC-205 antibody MG38.226 (Figure S1A,
available on the Blood website; see the Supplemental Materials link at
the top of the online article). A fusion with the heavy chain of the
isotype-matched antibody TIB93, specific for the mouse MHC class II
molecule H2-Ak, was also engineered as a control. The fusion mAbs
were produced by transient transfections into 293T cells and purified on
nickel-sepharose columns. The purified mAbs were characterized by
silver staining (Figure S1B) and by Western blot analysis using an
anti-EBNA1 antibody after SDS-PAGE (Figure S1C). To assess their
biologic activity, the fusion antibodies were tested for binding to CHO
cells transfected to express the human DEC-205 receptor as well as
human monocyte-derived immature DCs (Figure S2A). In addition,
both the DEC-205-EBNA1 and the isotype-EBNA1 fusion Abs were
used to stain frozen human spleen sections. Whereas the isotype control
failed to stain, the DEC-205-EBNA1 fusion protein was comparable
with the unconjugated DEC-205 Ab (Figure S2B), and stained DCs in
the T- and B-cell zones of human splenic white pulp.21 Although
localization of DCs has not been typically observed in B-cell zones of
murine spleens, scattered CD11c and DEC-205 cells are readily
detected in human splenic B-cell areas21,33 where they may be involved
in generating T-cell help for the strong humoral immune responses
generated upon DEC-205–targeted vaccination.34 In conclusion, our
DEC-205-EBNA1 fusion mAb recognizes DEC-205 expressed by
cells, including DCs in situ.
Expansion of EBNA1-specific T cells by
DEC-205-EBNA1–loaded DCs
As most people have protective immunity against EBV,10 we used
monocyte-derived DCs from healthy blood donors to evaluate their
ability in expanding EBNA1-specific memory T cells after loading
with DEC-205-EBNA1. The DCs were pulsed with the indicated
antibodies or an EBNA1 peptide library as a positive control. After
being matured with the TLR3/MDA-5 ligand poly(I:C), which has
been explored for in vivo use in humans and could therefore be
used as an adjuvant for clinical vaccination,35 the DCs were
cocultured with autologous PBMCs and EBNA1-specific T-cell
expansion was monitored by both IFN- production on day 9
(Figure 1A top panel) as well as by proliferation on day 15 (Figure
1A bottom panel) after restimulation with the EBNA1 peptide
library on day 9. In 11 of the 17 individuals we studied, the
frequency of IFN- CD4 and/or CD8 T cells expanded by
DEC-205-EBNA1–pulsed DCs and specific for EBNA1400-641
peptides was more than twice the number of T cells expanded as a
result of isotype-EBNA1 stimulation (Figure 1B). In addition, the
frequency of CD3 IFN- EBNA1-specific T cells expanded by
DEC-205-EBNA1 targeting ranged from 0.5% to 12.5%, whereas
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the expansion achieved by isotype-EBNA1 targeting only rarely
exceeded 2%. Although we were able to detect both CD8 and
CD4 IFN- EBNA1-specific T cells, the greater proportion of
the responding cells were of the CD4 kind, and more healthy
volunteers expanded EBNA1-specific CD4 T cells upon DEC-
205-EBNA1 stimulation than in response to isotype-EBNA1. To
reveal additional subdominant T-cell responses against EBNA1,
the already expanded T cells were labeled with carboxyfluorescein
succinimidyl ester (CFSE) and restimulated with an EBNA1
peptide library for 6 more days. The proliferation of the responding
cells was measured by monitoring CFSE dilution. Once again, we
observed that T cells cocultured with DEC-205-EBNA1–pulsed
DCs proliferated more vigorously in response to EBNA1 peptide
restimulation compared with T cells cocultured with isotype-
EBNA1–pulsed DCs (Figure 1C). Among the 17 individuals who
we studied, the mean of the frequency of EBNA1-specific CFSE-
low T cells was 42% in the DEC-205-EBNA1 group compared
with 29% in the isotype-EBNA1 stimulations (data not shown).
This difference was statistically significant (P value of .002).
Whereas we observed predominantly IFN-–secreting CD4T cells
after 9 days of coculture with DEC-205-EBNA1–pulsed DCs,
restimulation with the EBNA1 peptide library expanded EBNA1-
specific CD8 T cells in addition. For EBNA1-specific CD4
T cells, the second round of expansion, however, diminished
differences between DEC-205-EBNA1 and isotype-EBNA1–
mediated T-cell stimulation, which both supported antigen-specific
T-cell expansion to high levels at day 15. In conclusion, among most of
the 17 blood donors we processed, DEC-205-EBNA1 was approxi-
mately 2-fold more efficient as vaccine antigen formulation than the
isotype-EBNA1 in expanding EBNA1-specific T cells.
To further characterize the efficacy of targeting EBNA1 to
DEC-205, we pulsed monocyte-derived DCs with titrated doses of
the DEC-205-EBNA1 and isotype-EBNA1 antibodies. Consis-
tent with the results in Figure 1, DCs that took up EBNA1 via
DEC-205 at an antibody concentration of 1 g/mL expanded
antigen-specific T cells to more than 2-fold higher frequencies
compared with control isotype-EBNA1–targeted DCs (Figure 2;
P  .006 across all concentrations). More importantly, we found
that DCs loaded with 0.3 g/mL DEC-205-EBNA1 expanded
IFN-–secreting T cells just as efficiently as DCs that were pulsed
with 3 g/mL isotype-EBNA1. Thus, DEC-205–targeted EBNA1
expanded T cells at 10-fold lower concentrations than antigen
without targeting.
Expansion of EBNA1-specific T cells by DEC-205-EBNA1
addition to bulk PBMCs
Having established that loading of monocyte-derived DCs with
EBNA1 via the DEC-205 receptor mediates antigen presentation to
T cells, we next incubated our vaccine construct with bulk PBMCs,
Figure 1. Induction of EBNA1-specific T-cell responses by DEC-205-EBNA1 targeting to DCs. (A) PBMCs from blood donors were stimulated with mature autologous
monocyte-derived DCs that were pulsed with medium, EBNA1 peptides, 1 g/mL DEC-205-EBNA1, or control Ig-EBNA1 using poly (I:C) as an adjuvant. After 9 days,
frequencies of IFN- CD3 T cells were determined by intracellular staining after EBNA1 peptide restimulation (top row). After a second round of stimulation with an EBNA1
peptide library on day 9, proliferation was evaluated by CFSE dilution on day 15 (bottom row). Representative data of 17 experiments are shown. Percentages on plots are of
total cells within respective gates. Summary of the EBNA1-specific T-cell responses for 17 donors evaluated (B) by IFN- secretion on day 9 and (C) by CFSE dilution on day
15. Horizontal lines represent medians.
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in which the infrequent subset of BDCA3 myeloid DCs expresses
the highest levels of DEC-205.36 DEC-205-EBNA1 was added to
freshly isolated PBMCs with poly(I:C) as a DC maturation
stimulus, and EBNA1-specific T-cell expansion was monitored as
described for Figure 1. The frequency of IFN- CD3 T cells
ranged from 0.25% to 0.7% in the DEC-205-EBNA1–stimulated
PBMCs, whereas it was between 0.15% and 0.3% for the isotype-
EBNA1 group. Among the 6 tested PBMC donors, 4 of them had at
least 2 times more EBNA1-specific IFN-–secreting CD8 and/or
CD4 cells when stimulated with DEC-205-EBNA1 compared
with the isotype-EBNA1 stimulation (Figure 3A). Just as we had
observed in the DC/T-cell cocultures, upon restimulation with an
EBNA1 peptide library, CD8 T cells from DEC-205-EBNA1–
stimulated PBMCs proliferated much more vigorously than the
isotype-EBNA1 control–stimulated cultures (Figure 3B). The mean
of the frequency of EBNA1-specific CFSE-low T cells was 30% in
the DEC-205-EBNA1 group compared with 18% in the isotype-
EBNA1 (data not shown); the difference was statistically signifi-
cant (P value of .001). These findings indicate that DEC-205–
targeted EBNA1 is presented on MHC class I molecules in bulk
PBMC cultures, leading to EBNA1-specific CD8T-cell expansion.
Protection against EBV infection of B cells upon
DEC-205-EBNA1–mediated T-cell expansion
To test whether these expanded EBNA1-specific T cells were of
protective value, we tested their capacity to restrict EBV infection
of B cell in vitro. B cells, latently infected by EBV, express the
activation marker CD23; thus the outgrowth of infected cells can be
monitored by flow cytometric analysis of CD19 CD23 double-
positive cells. To assess whether memory T cells expanded from
DEC-205-EBNA1–pulsed bulk PBMCs could mediate the regres-
sion of autologous EBV-infected B cells, we cocultured the
stimulated PBMCs with the infected B cells at an effector to target
ratio of 1:2 for 16 days. In the absence of T cells, there was
outgrowth of 15% to 25% EBV-infected B cells. While addition of
T cells alone caused regression of EBV infection, stimulation of the
PBMCs with DEC-205-EBNA1 led to significantly elevated
regression compared with isotype-EBNA1 control stimulation
(Figure 4). Thus, by targeting EBNA1 to the DEC-205 receptor, we
could achieve expansion of protective EBNA1-specific memory
T cells that were able to significantly reduce EBV infection of
autologous B cells.
In vivo priming of EBNA1-specific T cells and antibodies by
DEC-205-EBNA1
In mice, in vivo targeting of antigens to DEC-205 enhances the
efficiency of antigen presentation to both CD4 and CD8
T cells.18,19 The ability of DEC-205-EBNA1 to expand antigen-
specific T cells in vitro encouraged us to test the potential of
DEC-205 targeting in vivo to initiate immune responses. For this
purpose, we used the NOD-scid IL2Rnull (NOG) immunodeficient
mouse reconstituted with human immune system components.
Upon injection with human CD34 hematopoietic stem cells, NOG
mice develop human B, T, natural killer (NK), and myeloid cells
including dendritic cells, and thus the mice represent a promising
model to study human immune responses in vivo37 (data not
shown). Using fluorescent immunohistochemistry, we could dem-
onstrate that the spleens of these mice contain DEC-205 MHC II
CD11c cells with dendritic cell morphology in proximity to CD3
T cells (Figure S3 and data not shown). Next, we immunized
reconstituted NOG mice intraperitoneally with DEC-205-EBNA1
or isotype-EBNA1 antibodies plus poly(I:C) as a DC maturation
stimulus, followed by a booster injection a month later. We tested
the efficacy of the vaccine using an IFN- ELISPOT assay to
compare splenic EBNA1 peptide-specific responses with nonspe-
cific responses against an influenza matrix protein 1 (MP1) peptide
library. Although we did not observe any EBNA1-specific IFN-
secretion one month after the boost, when the animals were killed
Figure 2. Dose-dependent response to DEC-205-EBNA1 targeting. Monocyte-
derived DCs were pulsed with increasing concentrations of DEC-205-EBNA1 (f) or
Ig-EBNA1 () control antibodies using poly(I:C) as a maturation stimulus. PBMCs
from the same donor were stimulated with the antigen-loaded and matured DCs for
9 days, and frequencies of EBNA1-specific IFN- CD3 T cells were determined by
intracellular staining after EBNA1 peptide restimulation. One of 2 evaluated donors is
shown.
Figure 3. DEC-205-EBNA1 in combination with poly(I:C) induces EBNA1-
specific T-cell responses in bulk PBMCs. PBMCs from blood donors were pulsed
with medium, 5 g/mL DEC-205-EBNA1, or isotype-EBNA1 using poly(I:C) as an
adjuvant and with 10 U/mL IL-2. EBNA1-specific (A) IFN- production on day 9 and
(B) proliferation by T cells on day 15 were determined as in Figure 1 for 6 different
donors. Horizontal lines represent medians.
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2 months after the booster injection, we detected a statistically
significant difference in EBNA1-specific T-cell responses between
the DEC-205-EBNA1–vaccinated animals and isotype-EBNA1–
injected controls by IFN- ELISPOT assays (Figure 5A; P  .01).
In 2 of the vaccinated animals with the highest EBNA1-specific
T-cell responses ( 20 IFN- spots per 105 splenocytes), we also
detected anti-EBNA1 IgM, but not IgG, antibodies (Figure 5B and
data not shown). Therefore, targeting viral antigens to the human
DEC-205 receptor in vivo has the potential to prime both human T-
and B-cell responses.
Discussion
Targeted in vivo delivery of antigens to DCs constitutes a
promising new avenue of vaccination. Although this approach has
been validated mainly in mice,13 we show here that targeting
EBNA1 to human DCs via DEC-205 in the presence of a DC
maturation stimulus is capable of expanding protective EBNA1-
specific CD4 and CD8 memory T cells. Targeting in bulk
PBMCs with DEC-205-EBNA1 antibody addition was also
efficient in expanding antigen-specific T cells, thus negating the
need for in vitro DC preparations. Furthermore, these expanded
lymphocytes could control the outgrowth of autologous EBV-
infected B cells. In addition, we demonstrate that DEC-205-
EBNA1 antibody vaccination of NOD-scid IL2Rnull mice with
reconstituted human immune system components can prime
EBNA1-specific human T- and B-cell responses. EBV infection of
human B cells followed by induction of primary HLA-restricted
EBV-specific human T cells has been previously reported in
2 mouse models of human immune system reconstitution.38,39
Hence, we suggest that DEC-205-EBNA1 fusion antibody vaccina-
tion was also able to induce primary human T- and, in a subset of
mice, B-cell responses in NOD-scid IL2Rnull mice with reconsti-
tuted human immune system components. Whether prior vaccina-
tion with DEC-205-EBNA1 will affect the outcome of EBV
infection and the accompanying T-cell responses will be interesting
to study and the topic of future research in our laboratory. We
observed that the frequency and breadth of the primary immune
responses in this mouse model of the human immune system were
modest and slow to develop compared with mouse DEC-205–
targeted vaccines tested in C57BL/6 and BALB/c mice. This may
be due to diminished secondary lymphoid organ and germinal
center formation in these and similarly reconstituted mice,40,41 and
comparable observations have been reported by other groups using
ovalbumin,42 tetanus toxoid,39 and Haemophilus influenzae type b
(HIB) conjugate vaccines43 as well as in the context of HIV
infection.32,44 Nevertheless, our results indicate that directing EBV
antigens to DEC-205 with poly(I:C) as an adjuvant may be a
feasible vaccine strategy in humans for the induction of primary
immune responses as well as for the expansion of protective
antigen-specific CD4 and CD8 memory T cells against EBV-
associated diseases.
Induction of primary immune responses as well as the expan-
sion of preexisting memory T cells specific for EBNA1 can
especially benefit Hodgkin and Burkitt lymphoma patients who
Figure 4. PBMCs primed by DEC-205-EBNA1 control EBV infection. Bulk PBMCs were pulsed with medium, 5 g/mL DEC-205-EBNA1, or control Ig-EBNA1 in
combination with poly(I:C) and 10 U/mL IL-2. After 9 days, the cells were restimulated and expanded with an EBNA1 peptide library for an additional 6 days at which point
autologous EBV-infected B cells were added into the culture and supplemented with 10 U/mL IL-2, 10 ng/mL IL-7, and 10 ng/mL IL-15. (A) After 16 days of coculture, outgrowth
of EBV-infected B cells was assessed by flow cytometric analysis of CD19 CD23 double-positive cells. Representative data of 6 experiments are shown. Percentages on
plots are of total cells within respective gates. (B) Summary of EBV-infected B-cell regression for 6 different donors.
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have deficiencies in their EBNA1-specific T-cell responses (K. N.
Heller, F. A., P. Steinherz, C. Postlook, A. Chadburn, K. Kelly,
C.M., manuscript submitted; Ann Moormann, Case Western Re-
serve University, written communication, April 2008). Moreover,
HIV-infected individuals who develop EBV-associated CNS or
non-Hodgkin lymphomas were also found to have decreased
EBV-specific CD4 T-cell responses.12,45 In the case of EBV-
associated non-Hodgkin lymphoma, this loss was particularly
pronounced for EBNA1-specific CD4 T cells, but affected CD4
T-cell responses to the lytic EBV antigen BZLF1 to a much lesser
extent.12 Although frequencies of EBV-specific T cells in periph-
eral blood of NPC patients were found to be similar to healthy
controls,46 the same study also found that a great majority of these
patients did not have detectable EBNA1-specific CD8 T cells.11
Because boosting preexisting EBNA1-specific CD4 and CD8
T cells via DEC-205 targeting leads to better control of EBV
infection (Figure 4), our vaccine strategy may benefit patients with
all types of EBV-associated malignancies by either correcting for a
selective loss of EBNA1-specific CD4 T-cell responses, as seen in
EBV-associated lymphomas, or increasing the generally low CD8
T-cell response to this antigen.
To avoid symptomatic primary EBV infection, and the in-
creased risk after IM to develop Hodgkin disease (HD) as well as
the autoimmune disease multiple sclerosis,47,48 vaccines to induce
neutralizing antibodies and T-cell responses are under develop-
ment. Along these lines, a phase 1/2 clinical trial with recombinant
EBV major surface glycoprotein gp350 as the vaccine antigen was
successful in eliciting neutralizing antibodies. Although this vac-
cine seemed to diminish the incidence of IM, its efficacy in
preventing virus infection and/or EBV-associated diseases remains
unknown.49,50 It seems unlikely that sterilizing immunity against
EBV can be achieved via vaccination because 1 to 10 virus
particles are enough for the establishment of lifelong -herpesvirus
infections,51,52 and reinfection of healthy EBV carriers with new
EBV strains has been documented.53,54 Thus, more recent immuno-
therapeutic approaches against primary EBV infection have concen-
trated on inducing T-cell responses to aid in asymptomatic serocon-
version, rather than preventing infection, and to target EBV-
associated malignancies. Along these lines, a single CD8 T-cell
peptide epitope–based vaccine for IM has been tested in a phase 1
clinical trial. Peptide-specific responses against the injected epitope
were detected in the vaccinated individuals, but the insufficient
number of recipients precluded assessment of vaccine efficacy.55
Therefore, no vaccine that completely prevents symptomatic EBV
infection has been developed, and we propose to evaluate DEC-205–
mediated EBV antigen targeting for induction of protective im-
mune responses against IM.
In addition to vaccination against symptomatic EBV seroconver-
sion, there is a need for therapeutic vaccination against EBV-
associated malignancies. One clinically successful passive immuni-
zation approach against EBV-positive tumors is the adoptive
transfer of antigen-specific T cells. EBV-specific T cells from
seropositive individuals can be expanded in vitro by coincubation
with autologous EBV-transformed B-lymphoblastoid cell lines
(LCLs), and infusion of these expanded lymphocytes into the
recipients of hematopoietic stem cell or solid organ transplants has
been successful in the treatment of EBV-induced posttransplanta-
tion lymphoproliferative disease (PTLD).56 However, the same
approach has resulted in limited responses to other EBV-positive
malignancies such as Hodgkin disease (HD) and nasopharyngeal
carcinoma (NPC). This is, in part, because HD and NPC, unlike
PTLD, express only 3 viral proteins (EBNA1, LMP1, and LMP2),
but LCLs tend to expand T cells reactive against the immunodomi-
nant EBNA3 antigens present in PTLD. To overcome this chal-
lenge, various recombinant viruses expressing T-cell epitopes from
EBNA1, LMP1, and LMP2 have been used to infect PBMCs to
expand T cells specific for these 3 viral antigens. These approaches
have resulted in expansion of CD8 T cells specific for EBNA1
and LMPs in vitro, and they were able to control outgrowth of
LMP-expressing tumors in mice57-59; however, the effectiveness of
this strategy in a clinical setting has not been evaluated. On the
other hand, DCs pulsed with CD8 T-cell epitopes of LMP2 were
injected into NPC patients and, although LMP2-specific CD8
cytotoxic T lymphocytes (CTLs) were detected, these LMP2-
specific responses were too weak and transient to achieve clinical
success against the tumors.60 Thus, vaccine strategies that aim to
expand only protective EBV-specific CD8 T-cell responses have
not proven sufficient as therapies against EBV-associated
malignancies.
Because CD4 T cells are necessary to maintain CD8 T-cell
immunity and can target infected cells directly,5,6,61 more recent
vaccine attempts have focused on inducing both CD4 and CD8 T
cells. In addition, stimulation of CD4 CTLs against EBV-infected
tumors might be crucial for Burkitt lymphoma where EBNA1 is the
only viral protein expressed and MHC class I antigen presentation
is severely impaired.62,63 To achieve simultaneous stimulation of
both CD4 and CD8 T cells against EBV antigens, several
recombinant viral vaccines have been developed to target dendritic
cells, as these cells are the most potent antigen-presenting cells in
Figure 5. Induction of primary T- and B-cell responses via DEC-205-EBNA1
vaccination in immunodeficient mice reconstituted with human immune sys-
tem components. Reconstituted mice were vaccinated intraperitoneally with PBS,
Ig-EBNA1, or DEC-205-EBNA1 using poly(I:C) as an adjuvant and boosted a month
later. Two months after boost, bulk splenocytes were harvested, stimulated with
either EBNA1 peptides or an influenza matrix protein 1 peptide library, and subjected
to an IFN- ELISPOT assay. (A) Ratio of EBNA1-specific IFN- spots to nonspecific
spots against the influenza peptides summarized for each vaccine group. Horizontal
lines represent medians.(B) IFN- spots/105 splenocytes and EBNA1 IgM levels
shown for 2 animals from each group. An index value of 1.1 or higher confirms the
presence of anti-EBNA1 antibodies. Error bars represent SD.
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the initiation of antiviral immune responses. Furthermore, DCs can
expand EBV-specific CD8 T cells more efficiently than LCLs64
and they can prime protective immune responses in vitro.65 DCs
infected in vitro with a recombinant adenovirus expressing the
EBV LMP2 antigen were able to expand LMP2-specific CD4 and
CD8 CTLs that could kill NPC cells.66 A modified vaccinia virus
vector encoding a fusion between the CD4 T-cell epitope-rich
C-terminal domain of EBNA1 and full-length LMP2 protein has
also been used to infect DCs in vitro, and the infected DCs were
able to reactivate both LMP2-specific CD8 and EBNA1-specific
CD4 memory T cells from seropositive donors.67 Although these
approaches have been successful in eliciting tumor-specific T cells,
generation of DCs in vitro is labor intensive, has to be performed
for every patient individually, and might be limited by the DC
number that can be derived. In addition, there are safety concerns
over the use of vaccinia and adenoviral vector–based vaccines in
humans. In contrast, we propose that in vivo targeting of viral or
tumor antigens directly to the endocytic receptor DEC-205, using
an antibody-based vaccine, may be safer and more effective.
Another advantage of DEC-205 targeting is that this receptor is
expressed on many DCs in the T-cell areas of human lymphoid
tissues, and this positioning would allow the DEC-205–targeted
vaccine to efficiently select specific clones of T cells that circulate
from the blood through lymphoid organs. Therefore, the expansion
of protective CD4 and CD8 T-cell responses against EBNA1 in
vitro and the priming of EBNA1-specific human T-cell responses in
vivo by the DEC-205-EBNA1 hybrid antibody suggest that
targeted EBV antigen delivery to DEC-205 in vivo should be
explored for preventive vaccination against symptomatic primary
EBV infection as well as for therapeutic immunization against
EBV-associated malignancies.
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